Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

Tabernero, Josep;Van Cutsem, Eric;Díaz-Rubio, Eduardo;Cervantes, Andrés;de Gramont, Aimery;et.al.
(2007) The American Society of Clinical Oncology Gastrointestinal Symposium — Location: Orlando(Fl) (19.January.2007)

Files

59836.pdf
  • Restricted Access
  • Adobe PDF
  • 166.61 KB
Request a copy

Details

Authors
  • Tabernero, Josep
    Author
  • Van Cutsem, EricKUL
    Author
  • Díaz-Rubio, Eduardo
    Author
  • Cervantes, Andrés
    Author
  • Humblet, YvesUCLouvain
    Author
  • de Gramont, Aimery
    Author
Show more
Abstract
Purpose This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX-4]) in the first-line treatment of epidermal growth factor receptor - expressing metastatic colorectal cancer (mCRC). Patients and Methods The activity of cetuximab plus oxaliplatin was investigated in colon cancer cell lines and xenograft models. In the clinical study, patients with mCRC received on day 1 of a 14 day cycle, cetuximab (initial dose 400 mg/m(2) during week 1, then 250 mg/m(2) weekly) followed by FOLFOX-4 (oxaliplatin 85 mg/m(2) on day 1; leucovorin 200 mg/m(2) on days 1 and 2, followed by fluorouracil 400 mg/m(2) bolus then 600 mg/m(2) intravenous infusion during 22 hours on days 1 and 2). Results The preclinical studies confirmed the supra-additive activity of cetuximab to oxaliplatin. In the clinical study, 43 patients were included, with a median age of 65 years ( range, 43 to 78 years). Response rates (RRs) were 79% (unconfirmed) and 72% (confirmed), with 95% disease control. Median progression-free survival (mPFS) and median duration of response were 12.3 and 10.8 months, respectively. Ten patients (23%) underwent resection with curative intent of previously unresectable metastases. After a median follow-up of 30.5 months, median overall survival (mOS) was 30.0 months. Cetuximab did not increase the characteristic toxicity of FOLFOX-4 and was generally well tolerated. Conclusion Cetuximab in combination with FOLFOX-4 is a highly active first-line treatment for mCRC, showing encouraging RR, mPFS, and mOS values. The treatment resulted in a high resectability rate, which could potentially result in an improved cure rate. This combination is under phase III development.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., Andre, T., Van Laethem, J.-L., Soulie, P., Casado, E., Verslype, C., Valera, J. S., Tortora, G., Ciardiello, F., Kisker, O., & de Gramont, A. (2007). Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology, 25(33), 5225-5232. https://doi.org/10.1200/JCO.2007.13.2183 (Original work published 2007)